Pharmafile Logo

Webcast | Smarter science, sharper strategy: Expert perspectives from ASCO® 2026

June 18, 2026 | ASCO, Congress, Pharma, healthcare, oncology, webinar 

Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.

- PMLiVE

Join our team for an expert debrief from ASCO® 2026. With a front-row seat across multiple client engagements, we’ll share the scientific highlights, attendee perspectives and strategic lessons from one of oncology’s most important annual gatherings, while exploring what smarter, more measurable congress engagement looks like in practice.

What we’ll cover

  • Key scientific and strategic themes emerging from ASCO® 2026
  • Attendee perspectives and trends shaping oncology congress engagement
  • Lessons from real-world client engagements and launch environments
  • Smarter approaches to congress strategy, engagement and measurement
  • Opportunities to drive sharper strategic decision-making through congress insights

The experts shaping the conversation

  • Mark Jackson, Managing Director, Emota, an Inizio Engage company
  • Matt Hoelzle, Chief Medical Officer, Inizio Evoke
  • Simon Davenport, Global Head of Exhibitions and Environments, Emota, an Inizio Engage company
  • Nick Bellomo, Director of Technology and Engagement, Inizio Medical
  • Jo Ann Saitta, Global Head of Data Strategy, Analytics, and AI, Inizio Ignite
  • Lynsey Holbrook, Global Client Development Director, Emota, an Inizio Engage company
Watch the webcast here.

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

What oncologists really want from booth strategy

Simon Davenport, Global Head of Environments, Emota, an Inizio Engage company  At this year’s ASCO® congress, the spotlight wasn’t just on science – it was on how the industry engages. Supporting over 30…

How smart spaces and real-time strategy transformed ASCO® 2025

Nick Bellomo, Director of Technology and Engagement, Inizio Medical ASCO® 2025 wasn’t just about oncology breakthroughs – it was also a showcase for how technology is redefining congress engagement. Supporting…

The science is shifting in oncology: Are you ready to evolve with it?

Patty Zipfel, PhD, SVP, Scientific Strategy, Inizio Evoke. This year’s ASCO® meeting spotlighted a bold shift in oncology: the possibility of curing metastatic disease. A new trial design in metastatic…

Reimagine health with Inizio.

At Inizio, we provide tailored, innovative solutions to help health and life sciences companies with their clinical development and commercialization journeys, maximizing patient access. Our experts guide you through each…

Kathy O’Connell joins Research Partnership as Senior Vice President, Business Development

Kathy has been working in the pharmaceutical market research industry for over 25 years. She has a diverse business background, with in-depth experience in progressively responsible sales, business development and…

Infographic: Therapy Watch Acute Myeloid Leukemia market snapshot

This Acute Myeloid Leukemia infographic offers a snapshot of the real-world patient insights collected by our Therapy Watch study, based on data collected from a panel of 220 physicians across…

Navigating the future of AI: Insights from EphMRA’s one day meeting in London

Authored by: Ellie Forde and Mark Braund, Directors

Research conducted for Johnson and Johnson published in scientific journal

Findings from a study conducted by Dr. Chris Gaj, Vice President at Research Partnership, has been published in Clinical Genitourinary Cancer.

Connecting our Inizio Advisory capabilities to help a client address a threat to the brand, guide strategy and improve brand performance

The challenge Our client knew that prescribing of a key brand in a major market had slowed and needed to understand which patient segments were impacted so they could address…

Autoimmune conditions: Living With syndicated patient reports

The prevalence of autoimmune conditions is increasing, and despite significant advancements in treatments, individuals affected by these diseases may not be receiving the most effective management and care. In our…